RDD Europe 2025, which took place in Estoril, Portugal May 6-9, welcomed approximately 490 delegates … [Read More...] about RDD Europe 2025 introduced “Inhalation 5.0”
RDD Europe 2025 introduced “Inhalation 5.0”
RDD Europe 2025 preview
The upcoming RDD Europe 2025 conference in Estoril, Portugal will mark the 20th anniversary of the … [Read More...] about RDD Europe 2025 preview
DDL 2024 in review
DDL 2024 drew the largest crowd ever in the 35-year history of the Drug Delivery to the Lung (DDL), … [Read More...] about DDL 2024 in review
Latest news
Transpire Bio acquires rights to develop Suzhou Intagrand’s ITG-1052 PDE4 inhibitor as an inhaled therapy for IPF and other respiratory diseases
Transpire Bio announced that it has acquired an exclusive license to develop Suzhou Intragrand Pharma's ITG-1052, a PDE4 inhibitor, as an inhaled therapeutic for the treatment of idiopathic pulmonary fibrosis and other respiratory diseases. The terms of the deal, which gives Transpire Bio … [Read More...] about Transpire Bio acquires rights to develop Suzhou Intagrand’s ITG-1052 PDE4 inhibitor as an inhaled therapy for IPF and other respiratory diseases
European Investment Bank makes €20 million investment in Leyden Labs to support development of antiviral nasal sprays
Leyden Laboratories has announced a €20 million venture debt financing deal with the European Investment Bank, with funds intended to support development of Leyden Labs’ antiviral nasal sprays, including PanFlu. The investment falls under the European Commission’s InvestEU program, specifically, … [Read More...] about European Investment Bank makes €20 million investment in Leyden Labs to support development of antiviral nasal sprays
Pediatric trial of Cessatech’s CT001 sufentanil / ketamine nasal spray meets primary endpoint
According to Cessatech, the Phase 2/3 Pediatric Study 0202 of the company's CT001 sufentanil / ketamine nasal spray in children with severe pain met its primary endpoint, with more than half of patients reporting pain relief at 15 minutes post dose and almost 90% reporting pain relief at 30 minutes. … [Read More...] about Pediatric trial of Cessatech’s CT001 sufentanil / ketamine nasal spray meets primary endpoint
RDD Europe 2025 introduced “Inhalation 5.0”
RDD Europe 2025, which took place in Estoril, Portugal May 6-9, welcomed approximately 490 delegates and 70 exhibitors from around the world to a meeting that focused on overcoming complex problems in order to advance inhaled and nasal drug delivery in a way that is more sustainable, personalized, … [Read More...] about RDD Europe 2025 introduced “Inhalation 5.0”
FDA issues Refuse to File letter regarding Savara’s BLA for Molbreevi molgramostim inhalation solution for the treatment of aPAP
According to Savara, the FDA has issued an RTF letter in response to the company's BLA for Molbreevi molgramostim inhalation solution for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP), citing insufficient CMC data. Savara completed its rolling BLA submission for Molbreevi in … [Read More...] about FDA issues Refuse to File letter regarding Savara’s BLA for Molbreevi molgramostim inhalation solution for the treatment of aPAP
Other recent news
- FDA approves Liquidia’s Yutrepia treprostinil DPI for PAH and for PH-ILD
- Nuance says Phase 3 ENHANCE-CHINA trial of nebulized ensifentrine met its primary endpoint
- FDA approves Ritedose’s generic albuterol sulfate inhalation solution, 0.5%
- Lupin announces plans to develop MDIs using Honeywell’s Solstice Air HFO-1234ze
- Rein Therapeutics initiates Phase 2 trial of its LTI-03 caveolin-1-related peptide DPI in IPF patients